Compare · BGLC vs CI
BGLC vs CI
Side-by-side comparison of BioNexus Gene Lab Corp (BGLC) and The Cigna Group (CI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BGLC and CI operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI carries a market cap of $77.37B.
- Over the past year, BGLC is down 17.9% and CI is down 17.7% - CI leads by 0.2 points.
- CI has been more active in the news (14 items in the past 4 weeks vs 1 for BGLC).
- CI has more recent analyst coverage (25 ratings vs 0 for BGLC).
- Company
- BioNexus Gene Lab Corp
- The Cigna Group
- Price
- $2.31-10.47%
- $275.55-1.49%
- Market cap
- -
- $77.37B
- 1M return
- -10.47%
- +1.90%
- 1Y return
- -17.94%
- -17.71%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 14
- Recent ratings
- 0
- 25
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Latest BGLC
- SEC Form 10-K filed by BioNexus Gene Lab Corp
- SEC Form NT 10-K filed by BioNexus Gene Lab Corp
- BioNexus Gene Lab Corp filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
- BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
- BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN's Multi-Billion Dollar Market
- BioNexus Gene Lab Corp filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events
Latest CI
- Director Foss Eric J was granted 782 shares, increasing direct ownership by 2% to 36,696 units (SEC Form 4)
- Director Mcclellan Mark B. was granted 782 shares, increasing direct ownership by 13% to 6,891 units (SEC Form 4)
- Director Zarcone Donna F was granted 782 shares, increasing direct ownership by 3% to 27,517 units (SEC Form 4)
- Director Hathi Neesha was granted 782 shares, increasing direct ownership by 23% to 4,151 units (SEC Form 4)
- Director Mazzarella Kathleen M was granted 782 shares, increasing direct ownership by 13% to 6,891 units (SEC Form 4)
- Director Kurian George was granted 782 shares, increasing direct ownership by 21% to 4,560 units (SEC Form 4)
- Director Ross Kimberly A. was granted 782 shares, increasing direct ownership by 17% to 5,294 units (SEC Form 4)
- Director Hennigan Michael J was granted 782 shares, increasing direct ownership by 138% to 1,350 units (SEC Form 4)
- Director Ozuah Philip was granted 782 shares, increasing direct ownership by 43% to 2,583 units (SEC Form 4)
- Director Wiseman Eric C was granted 782 shares, increasing direct ownership by 3% to 23,940 units (SEC Form 4)